XCancer

GPC3-Targeted PET Imaging of 18F-X12 in Hepatocellular Carcinoma

Description:

This is a diagnostic study. This clinical trial aims to evaluate the diagnostic performance and safety of the novel radiotracer 18F-X12 in patients with hepatocellular carcinoma (HCC), and to provide evidence supporting a new approach for its early diagnosis, accurate staging and recurrence assessment.

Sponsor:

Peking University First Hospital

Phase:

N/A

Contacts:

Meng Liu (PRINCIPAL_INVESTIGATOR)

Meixi Chen (CONTACT)

2511210177@bjmu.edu.cn

+86 010-83575252

Government Study Link:

NCT07795437 - Click here to see study on

ClinicalTrials.gov

X12

Isotope(s):
Target(s):
  • GPC3
Ligand Class: Peptides
Inclusion
  • Patients with clinically diagnosed HCC who have received 18F-FDG positron emission tomography/computed tomography (PET/CT) for clinical staging or post-treatment restaging, and able to independently cooperate with relevant examinations.
  • Patients with highly suspected hepatocellular carcinoma (HCC) (hepatic space-occupying lesion of undetermined nature on imaging examination) or pathologically confirmed HCC, with no prior systemic therapy (including immunotherapy, chemoradiotherapy, targeted therapy, etc.) or suspected tumor recurrence after previous treatment, and able to independently cooperate with relevant examinations.
Exclusion

Exclusion Criteria Not Yet Provided